Research graph
References from Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). Local targets link to admitted publications; unresolved targets remain external evidence.
